In the US, statistics illustrated that an estimated 74,690 cases were newly diagnosed bladder cancer, among which 15,580 were expected to die in 2014 [2]. Although it is believed that both environmental [3] and genetic factors [4,5], such as genetic polymorphism, chromosomal anomalies and epigenetic changes, play critical roles in the development of bladder cancer, the exact mechanisms of bladder carcinogenesis are still not well elucidated. Therefore, understanding the potential carcinogenetic mechanisms of these genetic changes is important to identify novel therapeutic targets and

prognostic biomarkers. PCI-34051 MicroRNAs (miRNAs) are small (20 ~ 23 nucleotides), endogenous, non-coding RNAs, which constitute a novel cluster of target gene regulators [6]. They are involved in various cellular

processes, including self-renewal, proliferation, metabolism and apoptosis, by inducing post-transcriptional gene repression via accelerating the degradation and/or blocking the translation of their target mRNAs [7]. The miRNA genes were Selleck Sapanisertib observed to be specifically deleted in leukemia initially illustrated the selleck inhibitor important role of miRNA in carcinogenesis [8]. Subsequent researches have demonstrated that the expression of specific miRNAs is altered in many types of cancer, which is associated with carcinogenesis and cancer progression [9–13]. Meanwhile, accumulating evidences illustrated that the development and progression of bladder cancer is closely related to the

aberrant expression of miRNAs [14]. The initial study of miRNA expression in bladder cancer was reported by Gottardo in 2007 and 10 up-regulated miRNAs were detected [15]. Previous miRNA microarray analysis illustrated that miR-320 is down-regulated in selleck breast cancer, acute myelogenous leukemia and colon cancer, revealing that miR-320 could probably act as a tumor suppressor in prohibiting the behavior of cancer [16–18]. It was reported that miR-320 could inhibit prostate cancer cell proliferation by down-regulating the Wnt/beta-catenin signaling pathway [19]. Additionally, miR-320a/c/d could inhibit the migration and invasion of hepatocellular cancer via targeting GNAI1, a crucial protein of multiple cellular signal transduction pathways [20]. Moreover, Iwagami et al. showed that miR-320c regulated the resistance of pancreatic cancer cells to gemcitabine via SMARCC1 (a core subunit of the switch/sucrose nonfermentable), suggesting that miR-320c could be a potential therapeutic target in pancreatic cancer [21]. Nevertheless, the potential mechanism of miR-320c in bladder cancer has not been well elucidated. In our present study, we further testified miR-320c expression pattern in bladder cancer tissue. Additionally, for the first time, we detected that miR-320c could suppress growth and motility of the human bladder cancer cell line T24 and UM-UC-3. The tumor inhibitive role and potential mechanisms of miR-320c on bladder cancer were determined.